Explore 3 Stock Ideas & Industry Insights Download Free Report

MabCure Inc

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-18T21:00:00Z
VOLUME
100
Market Cap
0.00M

Momentum Score

…

MabCure, Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure, Inc. in January 2008 to reflect its new business plan. MabCure, Inc. was founded in 2006 and is based in White Plains, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
-
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.50M
Revenue Per Share
0.01
Gross Profit TTM
0.50M
Debt / Equity
0.07
ROE
-125.15%
Net Debt
0.11M
ROCE
-18.31%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2011-12-31 2010-12-31 2009-12-31 2008-12-31 2007-12-31
Type yearly yearly yearly yearly yearly
Date 2011-12-31 2010-12-31 2009-12-31 2008-12-31 2007-12-31
Income before tax -12.26M -1.23M -1.37M -0.53M -
Net income -12.45M -1.43M -1.39M -0.53M -0.11M
Selling general administrative 0.82M 0.67M 0.73M 0.53M -
Selling and marketing expenses - - 0.21M - -
Gross profit 0.50M 0.00M 0.00M 0.00M -
Ebit -0.71M -1.02M -1.36M -0.54M -
Ebitda -0.68M -0.98M -1.31M -0.53M -0.11M
Depreciation and amortization 0.03M 0.04M 0.05M 0.01M -
Operating income -0.71M -1.02M -1.36M -0.54M -0.11M
Other operating expenses 1.21M 1.02M 1.36M 0.54M 0.11M
Interest expense 0.19M 0.21M 0.02M 0.00M -
Non recurring 11.40M 11.40M 11.40M - -
Income tax expense 0.19M 0.21M 0.02M 0.00M 0.11M
Total revenue 0.50M 0.00M 0.00M 0.00M -
Total operating expenses 1.21M 1.02M 1.36M 0.54M 0.11M
Cost of revenue 0.00M 0.00M 0.00M 0.00M -
Total other income expense net -11.56M -0.21M -0.01M 0.01M -
Net income from continuing ops -12.26M -1.23M -1.38M -0.52M -
Net income applicable to common shares -12.26M -1.23M -1.38M -0.52M -
Breakdown 2011-12-31 2010-12-31 2009-12-31 2008-12-31 2007-12-31
Type yearly yearly yearly yearly yearly
Date 2011-12-31 2010-12-31 2009-12-31 2008-12-31 2007-12-31
Total assets 4.81M 16.21M 18.94M 19.49M -
Intangible assets 4.60M 16.00M 18.49M 18.49M -
Other current assets 0.01M 0.01M 0.03M 0.02M -
Total liab 0.94M 0.48M 0.83M 0.29M 0.05M
Total stockholder equity 3.88M 15.72M 18.10M 19.21M -0.05M
Deferred long term liab - 0.02M - - -
Other current liab 0.04M 0.43M 0.18M 0.11M 0.05M
Common stock 0.06M 0.06M 0.06M 0.06M 0.03M
Retained earnings -15.51M -3.24M -2.01M -0.64M -0.11M
Other assets 0.01M 0.02M 0.00M 0.00M -
Cash 0.15M 0.00M 0.21M 0.81M -
Total current liabilities 0.94M 0.47M 0.78M 0.19M 0.05M
Net debt 0.11M 0.05M 0.44M -0.63M -
Short term debt 0.26M 0.04M 0.59M 0.09M -
Short long term debt 0.30M 0.20M 0.68M 0.19M -
Short long term debt total 0.26M 0.05M 0.65M 0.18M -
Other stockholder equity 19.35M 18.94M 20.08M 19.80M 0.02M
Property plant equipment 0.04M 0.12M 0.17M 0.17M -
Total current assets 0.16M 0.06M 0.28M 0.84M -
Net tangible assets -0.73M -0.28M -0.38M 0.72M -
Net receivables - 0.04M 0.03M 0.01M -
Long term debt - 0.02M 0.06M - -
Accounts payable 0.63M 0.29M 0.15M 0.10M 0.00M
Accumulated other comprehensive income -0.03M -0.03M -0.02M -0.01M 0.01M
Non currrent assets other - 0.02M 0.00M 0.00M -
Non current assets total 4.65M 16.15M 18.66M 18.66M -
Breakdown 2011-12-31 2010-12-31 2009-12-31 2008-12-31 2007-12-31
Type yearly yearly yearly yearly yearly
Date 2011-12-31 2010-12-31 2009-12-31 2008-12-31 2007-12-31
Change to liabilities 0.35M 0.15M 0.06M 0.09M -
Total cashflows from investing activities 0.05M -0.01M -0.04M -0.02M -
Net borrowings 0.16M 0.02M 0.49M -0.01M -
Total cash from financing activities 0.17M 0.50M 0.49M 1.44M 0.05M
Change to operating activities -0.01M 0.03M -0.02M -0.02M -
Net income -23.63M -1.23M -1.37M -0.53M -0.11M
Change in cash 0.14M -0.21M -0.60M 0.81M -0.04M
Begin period cash flow 0.00M 0.21M 0.81M - 0.04M
End period cash flow 0.15M 0.00M 0.21M 0.81M -
Total cash from operating activities -0.06M -0.69M -1.03M -0.46M -0.09M
Depreciation 0.03M 0.04M 0.04M 0.00M -
Other cashflows from investing activities 0.05M -0.00M -0.00M - -
Change to account receivables 0.04M -0.02M -0.02M -0.01M -
Sale purchase of stock 0.02M 0.50M 0.50M 1.30M -
Other cashflows from financing activities 0.28M 0.04M 0.54M 0.25M -
Change to netincome 11.78M 0.33M 0.29M 0.00M -
Capital expenditures 0.00M 0.01M 0.04M 0.17M 0.00M
Change in working capital 0.39M 0.16M 0.02M 0.06M 0.01M
Stock based compensation 0.21M 0.13M 0.24M - -
Other non cash items -0.69M 0.20M 0.05M 0.01M 0.01M
Free cash flow -0.06M -0.71M -1.08M -0.63M -0.09M

Peer Comparison*

Sector: Technology Industry: Solar

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MBCI
MabCure Inc
-
-%
0.00 - - 0.00 0.06 1.29 -0.05
FSLR
First Solar Inc
-
-%
151.95 13.14 11.49 3.84 2.17 3.54 8.58
NXT
Nextpower Inc.
-
-%
75.95 21.39 18.42 3.38 4.90 3.30 15.84
ENPH
Enphase Energy Inc
-
-%
21.98 136.61 18.32 6.79 9.24 6.51 53.17
XISHY
Xinyi Solar Holdings Limited
-0.70
13.21%
4.60 11.55 14.93 0.22 1.24 0.24 1.12

Profile*

MabCure Inc

MabCure, Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure, Inc. in January 2008 to reflect its new business plan. MabCure, Inc. was founded in 2006 and is based in White Plains, New York.

21 Sparrow Circle, White Plains, NY, United States, 10605

845 591 3144

3

Name Title Year Born
Mr. Jehu Thomas Degerold Hand Chief Exec. & Financial Officer and Director 1957
Kimberly Peterson Corp. Sec. NA
Mr. Jehu Thomas Degerold Hand Esq. Chief Executive & Financial Officer and Director 1957

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…